文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

扩大尿道口周围清洁对昏迷患者导管相关尿路感染的效果:一项随机对照临床试验

Efficacy of expanded periurethral cleansing in reducing catheter-associated urinary tract infection in comatose patients: a randomized controlled clinical trial.
PubMed 文献 · Crit Care · 2024-05-13
一句话结论在昏迷患者中,扩大尿道口周围清洁方案可降低短期(≤10天)留置导尿管的CAUTI发生率,女性和糖尿病患者获益更多。

该随机对照试验将昏迷患者随机分为实验组(扩大尿道口周围清洁方案,n=225)和对照组(常规尿道口周围清洁方案,n=221),比较置管后第3、7、10天CAUTI发生率及病原学结果。第10天实验组CAUTI发生率10.22%(23/225)显著低于对照组21.27%(47/221),P=0.001;细菌性CAUTI(4.89% vs 10.86%,P=0.02)和混合感染CAUTI(0.89% vs 4.07%,P=0.03)也显著降低。女性患者(9.85% vs 29.52%,P<0.05)和糖尿病患者(17.72% vs 40.85%,P<0.05)获益更明显。结论提示扩大尿道口周围清洁可减少昏迷患者短期导尿的CAUTI,尤其细菌性和混合性感染。

要点

  • 置管后第10天,扩大清洁组CAUTI发生率10.22%(23/225)显著低于常规清洁组21.27%(47/221),P=0.001。
  • 细菌性CAUTI发生率扩大清洁组4.89%(11/225)低于常规组10.86%(24/221),P=0.02;混合感染CAUTI 0.89%(2/225) vs 4.07%(9/221),P=0.03。
  • 女性患者CAUTI阳性率扩大清洁组9.85%(13/132)低于常规组29.52%(31/105),P<0.05。
  • 糖尿病患者CAUTI阳性率扩大清洁组17.72%(14/79)低于常规组40.85%(29/71),P<0.05。
  • 第3天和第7天CAUTI发生率两组差异无统计学意义(第3天2.22% vs 3.17%,P=0.54;第7天5.33% vs 8.14%,P=0.24)。

适用人群与场景

  • 昏迷患者,留置导尿管短期(≤10天)
  • 女性患者和糖尿病患者从扩大尿道口周围清洁方案中获益更多

处置流程与药物剂量

  • 实验组采用扩大尿道口周围清洁方案,对照组采用常规尿道口周围清洁方案

研究设计与关键结果

  • 研究类型:随机对照临床试验;样本量:实验组n=225,对照组n=221;人群:昏迷患者;干预:扩大尿道口周围清洁方案 vs 常规尿道口周围清洁方案;主要终点:置管后第3、7、10天CAUTI发生率。
  • 第3天CAUTI发生率:实验组5/225(2.22%) vs 对照组7/221(3.17%),P=0.54。
  • 第7天CAUTI发生率:实验组12/225(5.33%) vs 对照组18/221(8.14%),P=0.24。
  • 第10天CAUTI发生率:实验组23/225(10.22%) vs 对照组47/221(21.27%),P=0.001。
  • 细菌性CAUTI发生率:实验组11/225(4.89%) vs 对照组24/221(10.86%),P=0.02。
  • 真菌性CAUTI发生率:实验组10/225(4.44%) vs 对照组14/221(6.33%),P=0.38。
  • 混合感染CAUTI发生率:实验组2/225(0.89%) vs 对照组9/221(4.07%),P=0.03。
  • 女性患者CAUTI阳性率:实验组13/132(9.85%) vs 对照组31/105(29.52%),P<0.05。

证据类型、等级与局限

  • 证据类型:随机对照临床试验
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对昏迷并短期(≤10天)留置导尿管的患者,可采用扩大尿道口周围清洁方案以降低CAUTI发生率,尤其适用于女性和糖尿病患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The effect of the periurethral cleansing range on catheter-associated urinary tract infection (CAUTI) occurrence remains unknown. The purpose of this study was to evaluate the efficacy of expanded periurethral cleansing for reducing CAUTI in comatose patients.

METHODS: In this randomized controlled trial, eligible patients in our hospital were enrolled and allocated randomly to the experimental group (expanded periurethral cleansing protocol; n = 225) or the control group (usual periurethral cleansing protocol; n = 221). The incidence of CAUTI on days 3, 7, and 10 after catheter insertion were compared, and the pathogen results and influencing factors were analyzed.

RESULTS: The incidences of CAUTI in the experimental and control groups on days 3, 7, and 10 were (5/225, 2.22% vs. 7/221, 3.17%, P = 0.54), (12/225, 5.33% vs. 18/221, 8.14%, P = 0.24), and (23/225, 10.22% vs. 47/221, 21.27%, P = 0.001), respectively; Escherichia coli and Candida albicans were the most common species in the two groups. The incidences of bacterial CAUTI and fungal CAUTI in the two groups were 11/225, 4.89% vs. 24/221, 10.86%, P = 0.02) and (10/225, 4.44% vs. 14/221, 6.33%, P = 0.38), respectively. The incidences of polymicrobial CAUTI in the two groups were 2/225 (0.89%) and 9/221 (4.07%), respectively (P = 0.03). The percentages of CAUTI-positive females in the two groups were 9.85% (13/132) and 29.52% (31/105), respectively (P < 0.05). The proportion of CAUTI-positive patients with diabetes in the experimental and control groups was 17.72% (14/79), which was lower than the 40.85% (29/71) in the control group (P < 0.05).

CONCLUSION: Expanded periurethral cleansing could reduce the incidence of CAUTI, especially those caused by bacteria and multiple pathogens, in comatose patients with short-term catheterization (≤ 10 days). Female patients and patients with diabetes benefit more from the expanded periurethral cleansing protocol for reducing CAUTI.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Qin X, Zhao H, Qin W, et al. Efficacy of expanded periurethral cleansing in reducing catheter-associated urinary tract infection in comatose patients: a randomized controlled clinical trial. Crit Care. 2024. PMID: 38741134. doi:10.1186/s13054-024-04947-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。